InspireMD (NYSE:NSPR) Insider Sells $18,036.86 in Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,186 shares of the firm’s stock in a transaction on Friday, May 30th. The shares were sold at an average price of $2.51, for a total transaction of $18,036.86. Following the sale, the insider owned 1,079,601 shares in the company, valued at $2,709,798.51. The trade was a 0.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Price Performance

Shares of NSPR stock opened at $1.00 on Friday. The company has a market capitalization of $46.84 million, a price-to-earnings ratio of -1.33 and a beta of 0.82. The company’s fifty day moving average price is $1.38 and its 200-day moving average price is $1.66. InspireMD, Inc. has a one year low of $0.97 and a one year high of $2.93.

Analyst Ratings Changes

A number of research firms have recently weighed in on NSPR. Lake Street Capital set a $4.00 target price on shares of InspireMD in a report on Monday, May 4th. Maxim Group began coverage on shares of InspireMD in a report on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Piper Sandler restated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Finally, Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, InspireMD has a consensus rating of “Buy” and a consensus price target of $4.50.

Key Headlines Impacting InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

Hedge Funds Weigh In On InspireMD

A number of large investors have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new position in shares of InspireMD during the 1st quarter worth about $29,000. Virtu Financial LLC purchased a new position in shares of InspireMD during the 4th quarter worth about $31,000. XTX Topco Ltd purchased a new position in shares of InspireMD during the 4th quarter worth about $30,000. Orbimed Advisors LLC boosted its stake in shares of InspireMD by 46.9% during the 4th quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after purchasing an additional 1,000,000 shares during the period. Finally, Essex Investment Management Co. LLC purchased a new stake in InspireMD in the 4th quarter valued at about $203,000. 44.78% of the stock is owned by hedge funds and other institutional investors.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.